Lantheus Welcomes CMS CY27 Final Rule on Diagnostic Radiopharmaceuticals
Lantheus said it welcomes the CMS CY27 final rule, which it describes as advancing access to diagnostic radiopharmaceuticals.
Lantheus said it welcomes the CMS CY27 final rule, which it describes as advancing access to diagnostic radiopharmaceuticals.